Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Zevra Therapeutics stock

ZVRA
US4884452065
A2QLX7

Price

8.62
Today +/-
-0.39
Today %
-4.65 %
P

Zevra Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Zevra Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Zevra Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Zevra Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Zevra Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Zevra Therapeutics Stock Price History

DateZevra Therapeutics Price
11/15/20248.62 undefined
11/14/20249.03 undefined
11/13/20248.39 undefined
11/12/20248.57 undefined
11/11/20248.96 undefined
11/8/20249.00 undefined
11/7/20248.81 undefined
11/6/20248.81 undefined
11/5/20248.61 undefined
11/4/20248.55 undefined
11/1/20248.40 undefined
10/31/20248.15 undefined
10/30/20248.43 undefined
10/29/20248.26 undefined
10/28/20248.05 undefined
10/25/20247.75 undefined
10/24/20247.90 undefined
10/23/20248.01 undefined
10/22/20248.34 undefined
10/21/20248.54 undefined
10/18/20248.49 undefined

Zevra Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zevra Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zevra Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zevra Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zevra Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zevra Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zevra Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zevra Therapeutics’s growth potential.

Zevra Therapeutics Revenue, EBIT and net profit per share

DateZevra Therapeutics RevenueZevra Therapeutics EBITZevra Therapeutics Net Income
2029e349.29 M undefined0 undefined177.12 M undefined
2028e292.85 M undefined160.29 M undefined136.73 M undefined
2027e234.94 M undefined111.5 M undefined97.82 M undefined
2026e182.45 M undefined49.69 M undefined30.59 M undefined
2025e99.93 M undefined-14.4 M undefined-20.73 M undefined
2024e23.88 M undefined-74.21 M undefined-89.71 M undefined
202327.46 M undefined-49.6 M undefined-46.05 M undefined
202210.46 M undefined-24.85 M undefined-41.54 M undefined
202128.65 M undefined7.73 M undefined-62.9 M undefined
202013.29 M undefined-5.2 M undefined-12.76 M undefined
201912.84 M undefined-20.34 M undefined-24.52 M undefined
20180 undefined-55.5 M undefined-56.47 M undefined
20170 undefined-33.37 M undefined-43.39 M undefined
20160 undefined-36.38 M undefined-16.52 M undefined
20150 undefined-22.81 M undefined-54.66 M undefined
20140 undefined-16.44 M undefined-24.45 M undefined
20130 undefined-4.72 M undefined-5.23 M undefined
20120 undefined-5.34 M undefined-70,000 undefined

Zevra Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000012132810272399182234292349
--------8.33115.38-64.29170.00-14.81330.4383.8428.5724.7919.52
-------216.67200.0092.86260.0096.30113.0426.2614.2911.118.907.45
0000000000026000000
0-5-24-54-16-43-56-24-12-62-41-46-89-203097136177
--380.00125.00-70.37168.7530.23-57.14-50.00416.67-33.8712.2093.48-77.53-250.00223.3340.2130.15
0.150.150.150.460.910.921.121.853.9829.7734.4935.45000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Zevra Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zevra Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
2.5210.351.367.842.221.73.24.2112.382.867.74
00005201.92.41.47.216.12
00000.100.100.20.11.11.26
000000000000
00.102.81.52.81.91.51.61.21.91.82
2.52.110.354.174.44723.76.68.41159386.94
0.30.40.40.4221.832.421.81.53
00008.23.300015.4200
000000000000
0000000000069.23
000000000004.7
003.10.10.40.21.30.90.40.40.79.94
0.30.43.50.510.65.53.13.92.817.822.585.39
2.82.513.854.68552.526.810.511.2132.8115.5172.33
                       
19.819.924.2000000000
001.794.7102.6107.2154.6171.3192.1397401.8472.66
-20.5-25.7-50.2-104.8-121.3-164.7-221.2-245.7-258.5-267-308.6-399.78
0000000000100-43
000000000000
-0.7-5.8-24.3-10.1-18.7-57.5-66.6-74.4-66.413093.372.85
0.30.41.74.90.57.93.74.91.20.53.613.99
0.812.20604.60.35.82.9314.96
000000.10.1000.80.47.07
000000000000
03.903.40.23.53.50.20.604.737.7
1.15.33.98.36.711.511.95.47.64.211.773.72
00.118.118.591.29078.577.568.1012.85.07
000000000000
2.42.81637.85.88.52.8221.65.231.68
2.42.934.156.39798.581.379.570.11.61836.74
3.58.23864.6103.711093.284.977.75.829.7110.46
2.82.413.754.58552.526.610.511.3135.8123183.31
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Zevra Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Zevra Therapeutics's financial health and stability.

Assets

Zevra Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Zevra Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Zevra Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Zevra Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
0-5-24-54-16-43-56-24-12-8-41
00000000000
00000000000
00103-1-2-500-4
-40836-10161010122130
00003555000
00000000000
-4-4-14-20-29-33-54-23-110-18
00000000000
500-19-45273330-15-36
500-19-45273330-15-36
00000000000
03240640052-3812
0006400280077-4
03236161028421138
00-1-2-30000730
00000000000
10822-14-57-150108-46
-4.45-4.37-14.72-20.41-30.41-33.28-54.22-23.77-1.9710.34-18.81
00000000000

Zevra Therapeutics stock margins

The Zevra Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zevra Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zevra Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zevra Therapeutics's sales revenue. A higher gross margin percentage indicates that the Zevra Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zevra Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zevra Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zevra Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zevra Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zevra Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zevra Therapeutics Margin History

Zevra Therapeutics Gross marginZevra Therapeutics Profit marginZevra Therapeutics EBIT marginZevra Therapeutics Profit margin
2029e97.09 %0 %50.71 %
2028e97.09 %54.73 %46.69 %
2027e97.09 %47.46 %41.64 %
2026e97.09 %27.24 %16.77 %
2025e97.09 %-14.41 %-20.75 %
2024e97.09 %-310.76 %-375.68 %
202397.09 %-180.63 %-167.69 %
202297.09 %-237.57 %-397.13 %
202197.09 %26.98 %-219.55 %
202097.09 %-39.13 %-96.01 %
201997.09 %-158.41 %-190.97 %
201897.09 %0 %0 %
201797.09 %0 %0 %
201697.09 %0 %0 %
201597.09 %0 %0 %
201497.09 %0 %0 %
201397.09 %0 %0 %
201297.09 %0 %0 %

Zevra Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Zevra Therapeutics earnings per share therefore indicates how much revenue Zevra Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zevra Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zevra Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zevra Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zevra Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zevra Therapeutics Revenue, EBIT and net profit per share

DateZevra Therapeutics Sales per ShareZevra Therapeutics EBIT per shareZevra Therapeutics Earnings per Share
2029e6.64 undefined0 undefined3.37 undefined
2028e5.57 undefined0 undefined2.6 undefined
2027e4.46 undefined0 undefined1.86 undefined
2026e3.47 undefined0 undefined0.58 undefined
2025e1.9 undefined0 undefined-0.39 undefined
2024e0.45 undefined0 undefined-1.7 undefined
20230.77 undefined-1.4 undefined-1.3 undefined
20220.3 undefined-0.72 undefined-1.2 undefined
20210.96 undefined0.26 undefined-2.11 undefined
20203.34 undefined-1.31 undefined-3.21 undefined
20196.94 undefined-10.99 undefined-13.25 undefined
20180 undefined-49.55 undefined-50.42 undefined
20170 undefined-36.27 undefined-47.16 undefined
20160 undefined-39.98 undefined-18.15 undefined
20150 undefined-49.59 undefined-118.83 undefined
20140 undefined-109.6 undefined-163 undefined
20130 undefined-31.47 undefined-34.87 undefined
20120 undefined-35.6 undefined-0.47 undefined

Zevra Therapeutics business model

KemPharm Inc. is a biopharmaceutical company founded in Iowa in 2006. The company focuses on developing new drugs for the treatment of pain, neurological disorders, and psychiatric disorders. KemPharm uses its own proprietary technology platform to synthesize new drug molecules that have better efficacy, tolerability, and safety than existing medications. The business model of KemPharm is based on the development and commercialization of novel prodrugs. A prodrug is an inactive precursor of a drug that is converted into its active form in the body. KemPharm utilizes its proprietary technology platform to design specific chemical compounds that are converted into the active form by a biological enzyme naturally present in the body. The advantages of such prodrugs are improved bioavailability, longer duration of action, and reduced toxicity. KemPharm has several business divisions: Kempharm Discovery, Kempharm Clinical, Kempharm Licensing, Kempharm Manufacturing, and Kempharm Commercial. Kempharm Discovery is the division where research and development of new drugs are conducted. KemPharm has several prodrugs in the development phase, including KP415, KP484, and KP879, each being developed for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and epilepsy, respectively. KemPharm Clinical is the division where clinical trials and regulatory approval of new drugs are conducted. The company has conducted several phase II and phase III trials for its prodrugs and plans to obtain commercial approval for its first products in the coming years. KemPharm Licensing is the division where KemPharm licenses its technology platform to other companies. The company has already formed several partnerships with other pharmaceutical companies, including Acura Pharmaceuticals, KVK Tech, and Gurnet Point Capital. These partnerships aim to enable the use of KemPharm's prodrugs in other products and increase revenue. Kempharm Manufacturing is the division where KemPharm's drugs are manufactured. KemPharm collaborates with various generic drug manufacturers to produce and distribute its prodrugs. Kempharm Commercial is the division where KemPharm sells its prodrugs directly to patients and physicians. The company plans to sell its prodrugs through pharmaceutical industry distribution and specialized sales channels. Overall, KemPharm has a promising portfolio of prodrugs that have potential for many medical applications. The company has the potential to become a major player in the pharmaceutical industry. KemPharm Inc. is a biopharmaceutical company that was founded in Iowa in 2006. The company focuses on developing new drugs for the treatment of pain, neurological disorders, and psychiatric disorders. KemPharm utilizes its proprietary technology platform to synthesize new drug molecules that have better efficacy, tolerability, and safety compared to existing medications. KemPharm's business model is based on the development and commercialization of novel prodrugs. A prodrug is an inactive precursor of a drug that is converted into its active form within the body. Using its proprietary technology platform, KemPharm designs specific chemical compounds that can be converted into their active forms by a naturally occurring biological enzyme within the body. The advantages of these prodrugs include improved bioavailability, longer duration of action, and reduced toxicity. KemPharm operates in several business areas: Kempharm Discovery, Kempharm Clinical, Kempharm Licensing, Kempharm Manufacturing, and Kempharm Commercial. Kempharm Discovery is responsible for the research and development of new drugs. KemPharm currently has several prodrugs in the developmental stage, such as KP415, KP484, and KP879, each designed for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and epilepsy, respectively. KemPharm Clinical is responsible for conducting clinical studies and obtaining regulatory approval for new drugs. The company has conducted multiple phase II and phase III studies for its prodrugs and plans to obtain commercial approval for its first products in the upcoming years. KemPharm Licensing is responsible for licensing KemPharm's technology platform to other companies. The company has already formed partnerships with other pharmaceutical companies, including Acura Pharmaceuticals, KVK Tech, and Gurnet Point Capital. These partnerships enable the utilization of KemPharm's prodrugs in other products and contribute to revenue growth. Kempharm Manufacturing is responsible for the production of KemPharm's drugs. The company collaborates with various generic drug manufacturers to produce and distribute its prodrugs. Kempharm Commercial is responsible for the direct sales of KemPharm's prodrugs to patients and physicians. The company plans to sell its prodrugs through pharmaceutical industry distribution channels and specialized distribution channels. Overall, KemPharm has a promising portfolio of prodrugs with potential applications in various medical fields. The company has the potential to become a significant player in the pharmaceutical industry. Zevra Therapeutics is one of the most popular companies on Eulerpool.com.

Zevra Therapeutics SWOT Analysis

Strengths

  • Strong intellectual property portfolio, providing a competitive advantage and protecting KemPharm's innovations in drug development.
  • Robust pipeline of drug candidates that have shown promising results in early-stage clinical trials.
  • Strategic partnerships with leading pharmaceutical companies, enabling access to resources, expertise, and potential collaborations.
  • Experienced management team with a track record of successfully developing and commercializing pharmaceutical products.

Weaknesses

  • Limited financial resources, which may hinder the company's ability to fully exploit the potential of its pipeline or fund additional clinical trials.
  • Relatively small size compared to major pharmaceutical competitors, limiting KemPharm's marketing and distribution capabilities.
  • Dependency on the successful development and regulatory approval of its drug candidates, with inherent risks of clinical failures or delays.
  • Need for continuous investment in research and development to stay ahead in a highly competitive industry.

Opportunities

  • Growing demand for innovative pharmaceuticals to address unmet medical needs and improve patient outcomes.
  • Increasing awareness and acceptance of KemPharm's LAT platform technology, attracting potential licensing and partnership opportunities.
  • Expansion into global markets, leveraging strategic collaborations and licensing agreements to reach a wider patient population.
  • Potential for market exclusivity and revenue growth upon successful regulatory approval of KemPharm's drug candidates.

Threats

  • Intense competition within the pharmaceutical industry, with established companies and new entrants vying for market share.
  • Stringent regulatory requirements and potential delays in obtaining approvals for new drug candidates.
  • Pricing pressures and reimbursement challenges, impacting the profitability and market uptake of KemPharm's products.
  • Rapidly evolving technological advancements and shifting market dynamics, necessitating continuous innovation and adaptation.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zevra Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Zevra Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zevra Therapeutics shares outstanding

The number of shares was Zevra Therapeutics in 2023 — This indicates how many shares 35.452 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zevra Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zevra Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zevra Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zevra Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zevra Therapeutics stock splits

In Zevra Therapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Zevra Therapeutics.

Zevra Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.43 -0.69  (-60.58 %)2024 Q3
6/30/2024-0.44 -0.48  (-8.43 %)2024 Q2
3/31/2024-0.49 -0.4  (17.97 %)2024 Q1
12/31/2023-0.27 -0.4  (-46.15 %)2023 Q4
9/30/2023-0.3 -0.4  (-31.8 %)2023 Q3
6/30/2023-0.35 -0.15  (57.17 %)2023 Q2
3/31/2023-0.24 -0.34  (-43.34 %)2023 Q1
12/31/2022-0.18 -0.26  (-47.06 %)2022 Q4
9/30/2022-0.13 -0.19  (-43.29 %)2022 Q3
6/30/2022-0.12 -0.19  (-55.23 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Zevra Therapeutics stock

Eulerpool World ESG Rating (EESG©)

15/ 100

🌱 Environment

16

👫 Social

20

🏛️ Governance

10

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Zevra Therapeutics shareholders

%
Name
Stocks
Change
Date
5.74242 % Braun (Samuel J)3,021,66009/25/2023
4.68972 % BlackRock Institutional Trust Company, N.A.2,467,730266,1126/30/2024
4.59794 % Nantahala Capital Management, LLC2,419,435-33,9706/30/2024
3.48426 % The Vanguard Group, Inc.1,833,415129,4096/30/2024
2.20908 % Altium Capital Management LP1,162,416820,9556/30/2024
2.18089 % Woodline Partners LP1,147,583137,9666/30/2024
1.73748 % Geode Capital Management, L.L.C.914,264127,2446/30/2024
1.52033 % 683 Capital Management LLC800,00006/30/2024
1.36803 % State Street Global Advisors (US)719,85936,6876/30/2024
0.87096 % Retirement Planning Company of New England, Inc.458,30028,1076/30/2024
1
2
3
4
5
...
10

Zevra Therapeutics Executives and Management Board

Dr. Sven Guenther(50)
Zevra Therapeutics Executive Vice President - Research and Development (since 2012)
Compensation 1.08 M
Mr. R. LaDuane Clifton(49)
Zevra Therapeutics Chief Financial Officer, Treasurer, Secretary
Compensation 1.07 M
Mr. Joseph Saluri(55)
Zevra Therapeutics Independent Director
Compensation 236,007
Mr. Matthew Plooster(41)
Zevra Therapeutics Independent Director
Compensation 235,300
Dr. David Tierney(60)
Zevra Therapeutics Independent Director
Compensation 231,099
1
2
3
4

Most common questions regarding Zevra Therapeutics

What values and corporate philosophy does Zevra Therapeutics represent?

KemPharm Inc, a leading pharmaceutical company, embodies certain values and a strong corporate philosophy. With a commitment to innovation and excellence, KemPharm is dedicated to delivering breakthrough medications that improve patients' lives. The company prioritizes scientific research and development, aiming to create novel and effective therapies to address unmet medical needs. KemPharm also values integrity, transparency, and ethical practices in all aspects of their operations. Through collaborations and strategic partnerships, they strive to advance their mission of advancing healthcare. Overall, KemPharm Inc is driven by a vision of providing cutting-edge pharmaceutical solutions and making a positive impact on the well-being of individuals worldwide.

In which countries and regions is Zevra Therapeutics primarily present?

KemPharm Inc is primarily present in the United States.

What significant milestones has the company Zevra Therapeutics achieved?

KemPharm Inc has achieved several significant milestones in their journey. The company successfully gained FDA approval for their proprietary product, Apadaz, a combination drug for acute pain management. Another milestone was the launch and commercialization of their ADHD medication, Azstarys, which received FDA approval for the treatment of attention deficit hyperactivity disorder. Additionally, KemPharm established collaborations with renowned pharmaceutical companies, enabling the development and commercialization of their innovative prodrug-based therapies. These achievements demonstrate KemPharm's commitment to advancing healthcare solutions and solidify their position as a leader in the pharmaceutical industry.

What is the history and background of the company Zevra Therapeutics?

KemPharm Inc is a pharmaceutical company based in the United States. It was founded in 2006 and specializes in the discovery and development of innovative treatments for various medical conditions. KemPharm focuses on utilizing its proprietary Ligand Activated Therapy (LAT) platform technology to develop therapies that have improved safety and efficacy profiles. The company has a diverse pipeline of product candidates, including both clinical and preclinical stage assets, targeting numerous therapeutic areas. With a strong commitment to research and development, KemPharm is dedicated to delivering novel treatments to patients and making a positive impact in the healthcare industry.

Who are the main competitors of Zevra Therapeutics in the market?

The main competitors of KemPharm Inc in the market include pharmaceutical companies such as Purdue Pharma, Mallinckrodt Pharmaceuticals, and Pfizer.

In which industries is Zevra Therapeutics primarily active?

KemPharm Inc is primarily active in the pharmaceutical industry.

What is the business model of Zevra Therapeutics?

The business model of KemPharm Inc revolves around developing and commercializing innovative medications to address unmet medical needs. As a specialty pharmaceutical company, KemPharm utilizes its proprietary Ligand Activated Therapy (LAT) platform technology to enhance existing drug products, resulting in improved efficacy, safety, and patient compliance. By leveraging this platform, KemPharm aims to provide novel treatment options in various therapeutic areas such as attention-deficit/hyperactivity disorder (ADHD), pain management, and other central nervous system disorders. Through strategic partnerships and collaborations, KemPharm strives to bring valuable medications to market and ultimately contribute to improving patient outcomes and quality of life.

What is the P/E ratio of Zevra Therapeutics 2024?

The Zevra Therapeutics P/E ratio is -3.41.

What is the P/S ratio of Zevra Therapeutics 2024?

The Zevra Therapeutics P/S ratio is 12.8.

What is the Quality Investing of Zevra Therapeutics?

The Quality Investing for Zevra Therapeutics is 4/10.

What is the revenue of Zevra Therapeutics 2024?

The expected Zevra Therapeutics revenue is 23.88 M USD.

How high is the profit of Zevra Therapeutics 2024?

The expected Zevra Therapeutics profit is -89.71 M USD.

What is the business model of Zevra Therapeutics

KemPharm Inc. is a biopharmaceutical company that focuses on the development of new drugs, with a particular emphasis on pain therapy. The company utilizes its proprietary LAT (Ligand Activated Therapy) technology to develop modified pro-drugs that are converted into active molecules in the body. This concept allows for the development of medications with improved properties such as reduced toxicity, longer duration of action, and better bioavailability. In this article, we will describe KemPharm's business model and its various divisions and products. Business model: KemPharm concentrates on the development of innovative drugs, with a focus on pain therapy. The company utilizes its LAT technology to develop modified pro-drugs that exhibit improved pharmacological properties. KemPharm works closely with partners, including manufacturers and distributors, to bring its products to market. Divisions: KemPharm Inc. has several divisions focused on the development and commercialization of medications. These include: 1. Pain therapy: The company specializes primarily in pain therapy and has made significant advancements in the development of novel pain medications. Its flagship product is Apadaz, an oxycodone-based pain medication approved for acute pain treatment in the United States. The company has also developed KP415 and KP484, which are used for the treatment of attention deficit hyperactivity disorder (ADHD). 2. CNS disorders: KemPharm has also made advancements in the development of medications for the treatment of central nervous system (CNS) disorders. KP879 has been developed for the treatment of schizophrenia and bipolar disorders. 3. Narcolepsy: The company has expanded its portfolio to include medications for the treatment of narcolepsy. The main product, KP415, is a stimulant used for the treatment of both narcolepsy and ADHD. Products: KemPharm offers a wide range of products primarily used in pain and narcolepsy therapy. The key products include: 1. Apadaz: Apadaz is a pain medication containing oxycodone and acetaminophen. It is used for the treatment of acute pain and is approved in the US. 2. KP415: KP415 is a combination medication used for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD). The medication is a modified pro-drug containing dexmethylphenidate and has an extended duration of action. 3. KP484: KP484 is another modified pro-drug used for the treatment of ADHD. The medication contains hydrocodone and achieves its therapeutic effect through activation within the body. Conclusion: KemPharm Inc. is a biopharmaceutical company that focuses on the development of new drugs, with a particular emphasis on pain therapy. The company has made significant advancements in the development of unique medications and has achieved its goals. It offers a wide range of products and collaborates with partners to bring its products to market. Through its innovative solutions, KemPharm has gained an excellent reputation for quality, effectiveness, and safety.

What is the Zevra Therapeutics dividend?

Zevra Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Zevra Therapeutics pay dividends?

The dividend cannot currently be calculated for Zevra Therapeutics or the company does not pay out a dividend.

What is the Zevra Therapeutics ISIN?

The ISIN of Zevra Therapeutics is US4884452065.

What is the Zevra Therapeutics WKN?

The WKN of Zevra Therapeutics is A2QLX7.

What is the Zevra Therapeutics ticker?

The ticker of Zevra Therapeutics is ZVRA.

How much dividend does Zevra Therapeutics pay?

Over the past 12 months, Zevra Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zevra Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Zevra Therapeutics?

The current dividend yield of Zevra Therapeutics is .

When does Zevra Therapeutics pay dividends?

Zevra Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zevra Therapeutics?

Zevra Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Zevra Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zevra Therapeutics located?

Zevra Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zevra Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zevra Therapeutics from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did Zevra Therapeutics pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of Zevra Therapeutics in the year 2023?

In the year 2023, Zevra Therapeutics distributed 0 USD as dividends.

In which currency does Zevra Therapeutics pay out the dividend?

The dividends of Zevra Therapeutics are distributed in USD.

All fundamentals about Zevra Therapeutics

Our stock analysis for Zevra Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zevra Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.